Azacitidine shows promise for myelodysplastic syndromes

摘要

Two-year survival data for patients taking azacitidine-the first of a new class of agents for myelodysplastic syndromes(where dys-functioning bone marrow results in the production of malformed or immature blood cells)-have been released by biopharma-ceutical company Pharmion.